Premium
Biological Perspectives: The Role of Glutamate in Schizophrenia and Its Treatment
Author(s) -
Steele Debbie,
Moore Randy L.,
Swan Nancy A.,
Grant Joan S.,
Keltner Norman L.
Publication year - 2012
Publication title -
perspectives in psychiatric care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.538
H-Index - 35
eISSN - 1744-6163
pISSN - 0031-5990
DOI - 10.1111/j.1744-6163.2012.00333.x
Subject(s) - schizophrenia (object oriented programming) , glutamatergic , dopamine hypothesis of schizophrenia , neuroscience , glutamate receptor , psychiatry , psychology , cognition , neurotransmission , medicine , dopamine , receptor , dopaminergic
Schizophrenia is a heartbreaking, debilitating, youth-stealing, lifetime disorder for most individuals afflicted with it. While the serendipitous discovery of chlorpromazine 60 plus years ago and the subsequent “discoveries” since have significantly reduced positive symptoms, the devastation of negative/cognitive symptoms continues to ruin lives. Given the cost in lives and dollars that schizophrenia drains out of our society, neuroscientists will continue to explore better approaches to fighting this disorder. The hypoglutamate model appears promising, yet there are miles to go before we sleep. As Nestler et al. (2009, p. 398) deftly acknowledge, “. . . it is important to point out that postulating a role for abnormal glutamatergic neurotransmission in schizophrenia is akin to proposing that the brain is involved in schizophrenia since every single neuron in the brain receives thousands of excitatory synapses that utilize glutamate as their neurotransmitter.”